Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| B | 54.5 | -0.35% | -0.19 |
Earnings due: Apr 28
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Historical AGIO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Cup with Handle | Other | -0.09% | |
| Doji - Bearish? | Reversal | -0.09% | |
| Stochastic Reached Overbought | Strength | -0.09% | |
| Overbought Stochastic | Strength | -0.09% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 4.96% | |
| Inside Day | Range Contraction | 4.96% | |
| Down 3 Days in a Row | Weakness | 4.96% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 4.59% | |
| Cup with Handle | Other | 4.59% | |
| Outside Day | Range Expansion | 4.59% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 1% | about 4 hours ago |
| 10 DMA Support | about 4 hours ago |
| Down 2 % | about 4 hours ago |
| Down 1% | about 4 hours ago |
| Fell Below Previous Day's Low | about 4 hours ago |
Get a Trading Assistant
- Earnings date: 04/28/2021
Agios Pharmaceuticals, Inc. Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Cancers Hydrogen Metabolism Organic Chemistry Inborn Errors Of Metabolism Glutamate Agios Pharmaceuticals Glutaminase Pyruvate Kinase Deficiency
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 58.93 |
| 52 Week Low | 32.47 |
| Average Volume | 751,330 |
| 200-Day Moving Average | 44.72 |
| 50-Day Moving Average | 51.55 |
| 20-Day Moving Average | 51.87 |
| 10-Day Moving Average | 53.48 |
| Average True Range | 2.43 |
| ADX | 15.06 |
| +DI | 23.41 |
| -DI | 12.75 |
| Chandelier Exit (Long, 3 ATRs ) | 48.70 |
| Chandelier Exit (Short, 3 ATRs ) | 53.84 |
| Upper Bollinger Band | 56.13 |
| Lower Bollinger Band | 47.60 |
| Percent B (%b) | 0.83 |
| BandWidth | 16.44 |
| MACD Line | 1.04 |
| MACD Signal Line | 0.77 |
| MACD Histogram | 0.2667 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 57.80 | ||||
| Resistance 3 (R3) | 57.88 | 56.93 | 57.28 | ||
| Resistance 2 (R2) | 56.93 | 56.14 | 56.89 | 57.10 | |
| Resistance 1 (R1) | 55.81 | 55.65 | 55.34 | 55.73 | 56.93 |
| Pivot Point | 54.86 | 54.86 | 54.62 | 54.82 | 54.86 |
| Support 1 (S1) | 53.74 | 54.07 | 53.27 | 53.66 | 52.45 |
| Support 2 (S2) | 52.79 | 53.58 | 52.75 | 52.28 | |
| Support 3 (S3) | 51.67 | 52.79 | 52.10 | ||
| Support 4 (S4) | 51.59 |
